EFX · Equifax Inc · Insider Trading

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 5/28/2026.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Represents phantom stock units previously elected by the reporting person to be received as deferred compensation in lieu of annual cash retainer fees under the Company's Board of Directors Deferred Compensation Plan. Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable, at the election of the reporting person, upon the reporting person's termination of service as a director.

Represents phantom stock units previously elected by the reporting person to be received as deferred compensation in lieu of annual cash retainer fees under the Company's Board of Directors Deferred Compensation Plan. Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable, at the election of the reporting person, upon the reporting person's termination of service as a director.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.

The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $169.42 to $170.09, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.

The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $175.74 to $175.94, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.

The option vested in three equal annual increments beginning 5/4/2019.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.

The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $173.50 to $174.15, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.

The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $174.54 to $175.48, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.

The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $170.48 to $171.47, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.

The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $168.395 to $168.55, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.

The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $171.50 to $172.49, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.

The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $172.50 to $173.33, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

Represents phantom stock units previously elected by the reporting person to be received as deferred compensation in lieu of annual cash retainer fees under the Company's Board of Directors Deferred Compensation Plan. Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable, at the election of the reporting person, upon the reporting person's termination of service as a director.

Annual director grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 5/7/2027.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Annual director grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 5/7/2027.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Annual director grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 5/7/2027.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Annual director grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 5/7/2027.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Annual director grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 5/7/2027.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Annual director grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 5/7/2027.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Annual director grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 5/7/2027.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/4/2025.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Annual director grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 5/7/2027.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Annual director grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 5/7/2027.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/21/2025.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.

The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $173.98 to $174.78, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 280 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 280 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.

The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $171.986 to $172.975, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 280 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.

The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $172.986 to $173.975, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 280 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

The option vested in three equal annual increments beginning 5/4/2019.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.

The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $170.982 to $171.979, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 280 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

Represents phantom stock units previously elected by the reporting person to be received as deferred compensation in lieu of annual cash retainer fees under the Company's Board of Directors Deferred Compensation Plan. Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable, at the election of the reporting person, upon the reporting person's termination of service as a director.

Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 3/2/2029.

New hire equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests in three equal annual increments beginning 3/2/2027.

Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on February 25, 2029.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 285 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on February 25, 2029.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on February 25, 2029.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 400 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on February 25, 2029.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on February 25, 2029.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on February 25, 2029.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on February 25, 2029.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on February 25, 2029.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on February 25, 2029.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on February 25, 2029.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on February 25, 2029.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on February 25, 2029.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/21/2025.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/18/2025.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/4/2025.

Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.